Emicizumab Associated Rhabdomyolysis in Hemophilia A

Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Joseph A., Hayden, Stephanie, Asamoah, Alexander, Sharma, Vivek R., Jennings, David C., Raj, Ashok B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atlantis Press 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432407/
https://www.ncbi.nlm.nih.gov/pubmed/34595457
http://dx.doi.org/10.2991/chi.k.200924.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432407/
https://www.ncbi.nlm.nih.gov/pubmed/34595457
http://dx.doi.org/10.2991/chi.k.200924.001

Ejemplares similares